Aion Therapeutic Inc.
ANTCF
$0.012
-$0.003-20.00%
| Weiss Ratings | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.92 | |||
| Price History | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 25.00% | |||
| 60-Day Total Return | -6.25% | |||
| 90-Day Total Return | 305.41% | |||
| Year to Date Total Return | 305.41% | |||
| 1-Year Total Return | 316.67% | |||
| 2-Year Total Return | 35.14% | |||
| 3-Year Total Return | -83.89% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -62.50% | |||
| 52-Week Low % Change | 316.67% | |||
| Price | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.04 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jun 14, 2023 | |||
| 52-Week High Price (Date) | Mar 27, 2024 | |||
| Valuation | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.98M | |||
| Enterprise Value | 7.21M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -7.14% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 30.00 | |||
| Price/Book (Q) | 7.89 | |||
| Enterprise Value/Revenue (TTM) | 43.93 | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | -24.61 | |||
| Enterprise Value/EBIT | -11.05 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 315.90M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 416-460-3000 | |||
| Address | 700 West Georgia Street Vancouver, BC V7Y 1K8 | |||
| Website | www.aiontherapeutic.com/ | |||
| Country | Canada | |||
| Year Founded | 2011 | |||
| Profitability | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -397.68% | |||
| Profit Margin | -692.21% | |||
| Management Effectiveness | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -16.79% | |||
| Return on Equity | -- | |||
| Income Statement | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 164.50K | |||
| Total Revenue (TTM) | 164.50K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 121.30K | |||
| EBITDA (TTM) | -293.60K | |||
| EBIT (TTM) | -654.20K | |||
| Net Income (TTM) | -1.14M | |||
| Net Income Avl. to Common (TTM) | -1.14M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -74.94% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | 18.18% | |||
| Balance Sheet | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 261.10K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 661.20K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 772.00K | |||
| Current Ratio (Q) | 0.182 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 4.40M | |||
| Total Current Liabilities (Q) | 3.63M | |||
| Total Debt (Q) | 1.52M | |||
| Total Liabilities (Q) | 3.63M | |||
| Total Common Equity (Q) | 772.00K | |||
| Cash Flow | ANTCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -215.00K | |||
| Cash from Financing (TTM) | 439.70K | |||
| Net Change in Cash (TTM) | 258.60K | |||
| Levered Free Cash Flow (TTM) | 540.60K | |||
| Cash from Operations (TTM) | 84.50K | |||
